Scientists continue to investigate how cannabinoids may interact with the immune system, especially in conditions involving chronic inflammation and autoimmune responses. In the review “Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges,” researchers examined how cannabinoids may influence immune pathways connected to autoimmune disorders such as multiple sclerosis, rheumatoid arthritis, lupus, and type 1 diabetes. The review explored both hemp-derived cannabinoids and synthetic cannabinoid compounds and how they interact with the body’s endocannabinoid system. (ResearchGate)

Researchers highlighted that cannabinoids such as CBD, CBG, THC, and CBC may help regulate inflammatory signaling by interacting with receptors involved in immune balance, including CB1, CB2, TRPV, and PPAR receptors. The review discussed how cannabinoids demonstrated anti-inflammatory and immunomodulatory effects in preclinical studies, including reductions in pro-inflammatory cytokines and support for immune system regulation. These findings continue to support growing scientific interest in cannabinoids and their potential role in supporting overall wellness and balance within the body. (PMC)

The researchers also noted that while preclinical evidence is encouraging, additional human clinical studies are still needed to better understand dosing, safety, consistency, and long-term outcomes. As cannabinoid science evolves, studies like this continue helping researchers better understand how full-spectrum and multi-cannabinoid hemp formulations may interact with the body’s natural systems in unique and potentially beneficial ways. (ResearchGate)

Source

Khan YA, et al. Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges. Published May 1, 2026. (ResearchGate) https://pubmed.ncbi.nlm.nih.gov/42105814/